Loading organizations...
Key people at Phoenix Tissue Repair, Inc..
Phoenix Tissue Repair, Inc. develops PTR-01, an intravenously-administered recombinant collagen type VII protein replacement therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). This systemic treatment directly targets the disease's genetic root by restoring the critical protein needed for skin integrity, aiming for broad, disease-modifying effects.
Phoenix Tissue Repair acquired worldwide rights to the PTR-01 program in 2017. The therapy's initial development stemmed from Hal Landy, M.D., and Deborah Ramsdell at Lotus Tissue Repair. Their insight recognized the profound need for systemic collagen VII replacement to combat debilitating skin fragility, driving the program which advanced under Phoenix Tissue Repair, an affiliate of BridgeBio Pharma.
The company focuses on individuals living with RDEB, striving to improve their quality of life. Phoenix Tissue Repair envisions delivering the first systemic therapy that lessens chronic blistering and scarring while fundamentally restoring tissue function. Their objective is to transform the standard of care for this underserved patient population.
Phoenix Tissue Repair, Inc. (PTR) is a Boston-based biotechnology company and affiliate of BridgeBio Pharma, focused on developing PTR-01, a novel systemic protein replacement therapy using recombinant collagen type VII (rC7) for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder causing severe blistering, scarring, and pain.[1][3][4][6] PTR-01 is administered intravenously to address the root cause by replacing missing collagen 7, which anchors the epidermis to the dermis, and has shown rapid wound healing in Phase 2 trials while earning FDA Orphan Drug and Fast Track designations.[4][8] The company serves RDEB patients—estimated at thousands worldwide—and solves the unmet need for disease-modifying treatments beyond symptomatic wound care, with preclinical data demonstrating de novo anchoring fibril formation and improved survival in disease models.[4][6]
Incorporated around 2018, PTR has raised approximately $4-20 million and advanced PTR-01 through Phase 1/2 studies, with positive 2022 Phase 2 results signaling growth momentum toward potential Phase 3 trials.[1][2][4][5]
Phoenix Tissue Repair emerged from earlier development of PTR-01 at Lotus Tissue Repair, acquired by Shire, before PTR secured worldwide rights in 2017.[6] Formed as a BridgeBio Pharma affiliate around 2018-2020 and headquartered in Boston, the company built on this foundation to focus exclusively on RDEB therapies.[1][3][5][6] Key leadership includes Executive Chairman Sanuj K. Ravindran, M.D. (also CEO of BridgeBio affiliate PellePharm), Chief Medical Officer Hal Landy, M.D. (with prior PTR-01 involvement at Lotus and roles at BridgeBio ventures), Chief Operating Officer Deborah Ramsdell (early PTR-01 developer), and Study Director Dan Rudin, M.D.[6][7]
Pivotal early moments include FDA Fast Track Designation, Orphan Drug status, and progression to Phase 1/2 trials by 2020, with 2022 Phase 2 data showing durable wound healing—humanizing PTR's mission to transform lives for RDEB patients facing daily trauma from minor friction.[4][6][8]
Phoenix Tissue Repair rides the wave of precision medicine in rare genetic skin diseases, where gene therapy and protein replacement are transforming epidermolysis bullosa (EB) treatment amid growing investment in orphan drugs.[2][4] Timing aligns with regulatory incentives like FDA Orphan/Fast Track status, which accelerate rare disease approvals, and BridgeBio's ecosystem amplifying PTR's reach in a market underserved by daily care-only options.[3][6][8] Favorable forces include rising biotech funding for RDEB (affecting ~7,650 US/EU patients per related assets) and demand for fibrosis-reversing therapies, potentially extending PTR-01 to dystrophic EB (DEB) broadly.[2][7] PTR influences the ecosystem by validating systemic approaches, collaborating via BridgeBio, and advancing clinical data that could catalyze competitors like Abeona or Eloxx.[2][4]
PTR-01 appears poised for Phase 3 trials post-2022 Phase 2 success, with extension studies ongoing and potential expansion to broader DEB or fibrosis indications like keloids, driven by leadership's BridgeBio network.[2][4][7] Trends in orphan drug pricing ($250k-400k annually) and systemic rare disease therapies will shape its path, potentially yielding peak sales of $250-350M if approved. Influence may grow through BridgeBio integration or partnerships, evolving PTR from affiliate innovator to RDEB therapy leader—reinforcing its promise to move beyond bandages to genetic restoration.[2][4]
Key people at Phoenix Tissue Repair, Inc..
